-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, MbOkaRbyIbddOTDINTLjEonotnTLC8tEEgmpYMJjHSSAA/3WqQ/hUkXDlCdZ+AxA cOgEeu3jrFJ+hLOAE+UjOQ== 0000922247-96-000009.txt : 19960724 0000922247-96-000009.hdr.sgml : 19960724 ACCESSION NUMBER: 0000922247-96-000009 CONFORMED SUBMISSION TYPE: S-8 PUBLIC DOCUMENT COUNT: 4 FILED AS OF DATE: 19960722 EFFECTIVENESS DATE: 19960810 SROS: NONE FILER: COMPANY DATA: COMPANY CONFORMED NAME: CYCLODEXTRIN TECHNOLOGIES DEVELOPMENT INC CENTRAL INDEX KEY: 0000922247 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 593029743 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-8 SEC ACT: 1933 Act SEC FILE NUMBER: 333-08547 FILM NUMBER: 96597200 BUSINESS ADDRESS: STREET 1: 3713 SW 42ND AVE STREET 2: STE 3 CITY: GAINESVILLE STATE: FL ZIP: 32608-6581 BUSINESS PHONE: 3523756822 S-8 1 Registration No. 333-_______ SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 _____________________ CYCLODEXTRIN TECHNOLOGIES DEVELOPMENT, INC. (Exact name of registrant as specified in its charter) Florida 59-3029743 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) 3713 S.W. 42nd Avenue. Suite 3, Gainesville, Florida 32608-6581 (Address of principal executive office) (Zip Code) Bruce Brashear, Esq. 920 N.W. 8th Avenue, Suite A Gainesville, Florida 32601 (352) 336-0800 (Name, address and telephone number, including area code, of agent for service) _______________ Independent Consulting Services Agreement with Diversified Corporate Consulting Group, LLC (Full Title of the Plan) _______________ CALCULATION OF REGISTRATION FEE
Title Amount to be Proposed maximum Proposed maximum Amount of of Securities registered offering price aggregate offering Registration fee per share price Common Stock, par value $.0001 110,010 $1.25 $171,891 $100 The price stated above is estimated solely for the purpose of calculation of registration fee and is based on the average of the high and low prices paid for a share of the Company's Common Stock on July 17, 1996.
PART I Item 1. Plan Information Consulting Services Agreements The Independent Consulting Services Agreement entered into May 22, 1996, between Cyclodextrin Technologies Development, Inc. (the "Company") and Diversified Corporate Consulting Group, LLC (the "Consultant") requires the Company to pay Consultant 110,010 shares of the Company's Common Stock as compensation for consulting services. Under the terms of the Independent Consulting Services Agreement, Consultant has agreed to provide long-term financial, operational and public relations planning and services. The Common Shares are fully vested at the time of issuance. Item 2. Registrant Information and Employee Plan Annual Information Plan participants may obtain, without charge, upon written or oral request, any of the documents incorporated by reference in Item 3 of Part II of this Registration Statement; these documents are incorporated by reference in the Section 10(a) prospectus which is a part of this Registration Statement. Plan participants may also obtain, without charge, upon written or oral request, any other documents required to be delivered to employees pursuant to Rule 428(b). All requests for documents should be directed to: Cyclodextrin Technologies Development, Inc., Attention: President, 3713 S.W. 42nd Avenue, Suite 3, Gainesville, FL 32608-6581; telephone 352-375-6822. PART II Item 3. Incorporation of Documents by Reference The following documents are incorporated by reference into this Registration Statement, and are made a part hereof: (a) The Registrant's latest annual report for the year ended December 31, 1995, on Form 10-KSB filed on or about March 30, 1996. (b) The Registrant's latest quarterly report for the quarter ended March 31, 1996, on Form 10-QSB filed on or about May 15, 1996. (c) All other reports filed by the registrant pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Form 10-KSB referred to in paragraph (a) above. (d) The descriptions of the registrant's securities which are contained in its registration statements filed under section 12 of the Securities Exchange Act of 1934, including any amendment or reports filed for the purpose of updating such descriptions. All reports filed by the Registrant pursuant to Section 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, after the date of this Registration Statement and prior to the filing of a post-effective amendment indicating that all of the securities offered hereby have been sold, or deregistering all such securities then remaining unsold, shall be deemed to be incorporated by reference and to be a part hereof from the date of filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is incorporated or deemed incorporated by reference herein modifies or supersedes such statement. Any such document so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement. Item 4. Description of Securities. Not Applicable. Item 5. Interests of Named Experts and Counsel. Not Applicable. Item 6. Indemnification of Officers and Directors. The By-Laws of the Company, contain a provision under which the officers and directors of the Company would be indemnified to the full extent permitted by law. Also, Sec. 607.0850, Fla. Stat. (1995), permits indemnification against expenses actually and reasonably incurred by a director, officer, employee or agent to the extent that such person has been successful in the defense of a matter eligible for indemnification under the statute. Under certain circumstances, expenses may be paid by a corporation in advance, subject to repayment, unless the defendant ultimately is determined to be ineligible for indemnification. In addition, the statute permits a corporation to indemnify directors and officers against certain liabilities and to purchase and maintain director and officer liability and reimbursement insurance against liabilities, whether or not the corporation would have the power of indemnification against such liabilities. Item 7. Exemption from Registration Claimed. Not Applicable. Item 8. Exhibits. Page (4) Instruments defining the rights of security holders, including indentures (a) Independent Consulting Services Agreement between Cyclodextrin Technologies Development, Inc. and Diversified Corporate Consulting Group, LLC dated May 22, 1996 (5) Opinion re legality (15) Letter re unaudited interim financial information None (24) Consents of experts and counsel (a) Consent of James Moore & Co. , L.P. (b) Consent of Bruce Brashear, Esq. (28) Additional exhibits None (29) Information from reports furnished to state insurance regulatory authorities None Item 9. Undertakings. (a) The undersigned registrant hereby undertakes: (1) To file, during any period in which it offers or sells securities, a post-effective amendment to this registration statement to include any additional or changed material information on the plan of distribution. (2) That, for the purpose of determining any liability under the Securities Act of 1933 treat each post-effective amendment as a new registration statement of the securities offered, and the offering of the securities at that time to be the initial bona fide offering. (3) File a post-effective amendment to remove any of the securities that remain unsold at the end of the offering. (b) The undersigned registrant hereby undertakes that, for the purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. (h) Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended (the "Act"), may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. SIGNATURES Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies it has reasonable grounds to believe it meets all the requirements for filing on Form S-8 and has duly caused same to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Gainesville, State of Florida, on the ___ day of ________________, 1996. Cyclodextrin Technologies Development, Inc. By: ___________________________________ C.E. Rick Strattan, President and Chief Executive Officer, Chairman of the Board, KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints C.E. Rick Strattan his true and lawful attorney-in-fact and agent with full power of substitution and resubstitution for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits hereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done on or about the premises, as fully and for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities indicated, on the dates indicated. Signature Title ________________________________ Chairman of the Board, President, CEO C. E. RICK STRATTAN Date: __________________________
EX-4 2 INSTRUMENTS DEFINING RIGHTS OF SECURITY HOLDERS May 22, 1996 Mr. C.E. Rick Strattan President Cyclodextrin Technologies Development, Inc. 3713 Southwest 42nd Avenue, Suite 3 Gainesville, Florida 32608-2531 By Facsimile Transmission to (352) 375-8287 Re: Professional Engagement Dear Mr. Strattan: This letter confirms the terms pursuant to which we have been engaged by Cyclodextrin Technologies Development, Inc., a Florida corporation (the "Company"), to provide the following services: Diversified Corporate Consulting Group. LLC's Responsibilities 1. Recruit and retain at least five market makers for the Company's common stock. 2. Recruit and supervise a financial public relations firm acceptable to the Company's Board of Directors, to assist the Company to disseminate information required in order to permit its securities to realize their proper trading value. 3. Use our best efforts to introduce the Company to at least two journalistic publications in multiple media, and to encourage such publications to feature the Company's progress in communications to subscribers. 4. (a) Assist the Company to raise required debt or equity capital through introductions to investment banking firms and individual investors, when and if necessary; and (b) Assist the Company to list its securities, if eligible, for trading on either one or more national securities exchanges or on the NASDAQ inter dealer quotation system. 5. Use best efforts to induce retail securities brokerage firms to consider the Company's securities as appropriate investments for their retail clients. 6. Assist the Company to effect corporate restructuring designed to maximize its operational efficiency, initiate an acquisitions program, and develop programs to assure compliance with applicable securities laws, with initial legal services to be provided through your legal counsel. 7. If required, train Company personnel and consultants in proper procedures for regulatory compliance and to effect its various strategic and tactical plans. 8. Develop programs to assist it to comply with the electronic filing requirements of Securities and Exchange Commission Regulation ST. Terms of Engagement 1. Except as described below with reference to the services described above (which are to be completed within 12 months after the date of this engagement letter), we will bill at out standard hourly rates for all work as to which a prior written arrangement with different terms has not been entered into. Any documents prepared by us on existing forms will be subject to a $50 per page initial licensing fee augmented by the time spent in personalizing the subject form. 2. Notwithstanding the foregoing, during the initial 185 days of our representation, we will accept and you will pay to us common stock of the Company, in a quantity equal to 10% of all outstanding common stock (subject to anti-dilutive rights), registered on Securities and Exchange Commission Form S-8 in lieu of document licensing fees and of required cash payments for up to an aggregate of 130 hours of our hourly and licensing fees. 3. Unless requested by you to the contrary, work will be performed by the person with the lowest billing rate and the requisite knowledge and experience. 4. All work requiring legal review will be submitted for approval by you to your legal counsel prior to its use, or, in the alternative, we will engage legal counsel to conduct such review on your behalf. In the latter case, our general counsel will review legal matters pertaining to states in which it is licensed to practice law and matters pertaining to other states will be referred to attorneys licensed in such other states. Payment of all balances due such unrelated attorneys will be your responsibility, notwithstanding our collection function. 5. In addition to our hourly fees, you will be responsible for payment of all costs and disbursements associated with our services. All statements will be paid within 10 days after receipt. In the event additional time is required, the Firm will have the option of selling the account receivable and you agree to pay interest thereon at the monthly rate of 1%. In the event collection activities are required you agree to pay all of our out of pocket costs associated therewith. There will be no change or waiver of the provisions contained herein, unless such change is in writing and signed by you and the Firm. 6. Diversified Corporate Consulting Group, LLC, shall have a right of first refusal to arrange all financing for the Company and its affiliates (whether debt or equity, foreign or domestic), during the initial 12 months of this engagement and shall be kept apprised of all capital raising activities by the Company, whether on a debt or equity basis. 7. (a) The Company shall supply Diversified Corporate consulting Group, LLC, on a regular and timely basis with all approved data and information about the Company, its management, its products, and its operations and Company shall be responsible for advising Diversified Corporate Consulting Group, LLC of any fact which would affect the accuracy of any prior data and information supplied to Diversified Corporate Consulting Group, LLC. (b) The Company shall use its best efforts to promptly supply Diversified Corporate Consulting Group, LLC with full and complete copies of all filings with all federal and state securities agencies; with full and complete copies of all shareholder reports and communications whether or not prepared with Diversified Corporate Consulting Group, LLC's assistance, with all data and information supplied to any analyst, broker-dealer, market maker, or other member of the financial community; and with all product/services brochures, sales materials, etc. (c) The Company shall promptly notify Diversified Corporate Consulting Group, LLC of the filing of any registration statement for the sale of securities and/or of any other event which triggers any restrictions on publicity. (d) The Company shall notify Diversified Corporate Consulting Group, LLC if any information or data supplied by the Company to Diversified Corporate Consulting Group, LLC has not been released or promulgated to the public. (e) The Company shall be deemed to make a continuing representation of the accuracy of any and all materials facts, material, information, and data which it supplies to Diversified Corporate Consulting Group, LLC and the Company acknowledges it awareness that Diversified Corporate Consulting Group, LLC will rely on such continuing representation in disseminating such information and otherwise performing its functions under this engagement letter. (f) Diversified Corporate Consulting Group, LLC, in the absence of notice in writing from the Company, may rely on the continuing accuracy of material, information and data supplied by the Company. 8. Final drafts of any matters prepared by us will be reviewed by you and, if legally required, by legal your counsel, to assure that: (a) All required information has been provided; (b) All materials are presented accurately; and, (c) That no materials required to render information provided "not misleading" are omitted. Only after such review and approval by you and, if required, your legal counsel, will any documents be filed with regulatory agencies or provided to third parties. Financial data will be reviewed by competent, independent, certified public accountants to be separately retained by you. If required by you, we will assist in selection and supervision of such attorneys and accountants. Such accountants will be required to review and approve all financially related filings, prior to submission to the appropriate regulatory authorities. 9. In the event our services are provided for the benefit of juridical entities other than the company, no materials for which we are responsible will be submitted to third parties until they have been reviewed and approved as to form and content by all executive officers, directors, partners, joint venturers or persons performing similar roles for the subject juridical entity. The filing of materials prepared by us with any governmental agency or provision of copies thereof to other persons shall be deemed presumptive evidence that our materials have been reviewed and approved as heretofore described. Due Diligence Materials We will upon receipt of a signed copy of this engagement letter, provide you with the following materials: 1. Officers & Directors Questionnaires to be completed by all officers, directors and principal consultants to entities for which we perform services at your request, and then returned to us: 2. A Company Questionnaire to be completed by a knowledgeable person or persons designated by entities for which we perform services at your request and then returned to us; 3. A memorandum prepared by us acquainting you with the requirements of Securities and Exchange Commission Regulation S-B, which governs the bulk of required Securities and Exchange Commission disclosure, both in conjunction with Fund raising activities and with periodic reporting obligations. In the event that you desire different arrangements, either in general or for specific projects, we will be glad to consider your proposals; however, all contrary arrangements must be memorialized in a written instrument signed by this firm. Please sign a copy of this transmission and return it to us by facsimile transmission to (352) 245-5913. We look forward to a pleasant and mutually profitable relationship. Very truly yours, Diversified Corporate Consulting Group, LLC William A. Calvo, III Managing Member The foregoing is hereby accepted as of the date first above written Mr. C.E. Rick Strattan President Cyclodextrin Technologies Development, Inc. EX-5 3 LEGAL OPINION AND CONSENT July 19, 1996 Securities and Exchange Commission 450 Fifth Street, N.W. Washington, DC 20549 RE: Registration Statement on Form S-8 Cyclodextrin Technologies Development, Inc. Gentlemen: I have acted as counsel for Cyclodextrin Technologies Development, Inc. (the "Company") in connection with its proposed offering to certain consultants of Company of 110,010 common shares (par value $.0001). In connection with the proposed public offering and above-described registration statement, I have reviewed the following: 1. The Certificate of Incorporation and amendments thereto of the Company; 2. The By-Laws and amendments thereto of the Company; 3. The minute books of the Company; and On the basis of such investigation and the examination of such other records as I deemed necessary, I am of the opinion that: a) the Company has been duly incorporated and is validly existing under the laws of the State of Florida; and b) The 110,010 shares have been duly authorized and when issued, will be legally issued by the Company and will be fully paid and nonassessable. I consent to the filing of this opinion as an Exhibit for the purpose of registering all or a portion of the Common Shares described in Form S-8 under the relevant state and federal securities laws. Sincerely, /s/ Bruce Brashear Bruce Brashear, Esq. EX-23 4 CONSENT OF EXPERT CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS Cyclodextrin Technologies Development, Inc. We hereby consent to the incorporation by reference on the Registration Statement on Form S-8 of our report dated February 5, 1996, included in the Form 10KSB of Cyclodextrin Technologies Development, Inc. for the year ended December 31, 1995. /s/ James Moore & Co., L.P. James Moore & Co., L.P. Gainesville, Florida July 22, 1996
-----END PRIVACY-ENHANCED MESSAGE-----